Article Data

  • Views 764
  • Dowloads 126

Original Research

Open Access

Ursolic acid inhibits NLRP3 inflammasome activation and alleviates vascular smooth muscle injury in Kawasaki disease

  • Guoqing Chen1,2
  • Yanru Wang2
  • Ying Zhang2
  • Fang Gu2
  • Tong Yu2,*,

1Graduate School, Zhejiang Chinese Medical University, 310014 Hangzhou, Zhejiang, China

2Center for Reproductive Medicine, Department of Pediatrics, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, 310014 Hangzhou, Zhejiang, China

DOI: 10.22514/sv.2024.041 Vol.20,Issue 4,April 2024 pp.46-51

Submitted: 13 December 2023 Accepted: 12 March 2024

Published: 08 April 2024

*Corresponding Author(s): Tong Yu E-mail: Yutong_688@163.com

Abstract

Kawasaki disease (KD) is a kind of autoimmune disease with systemic vasculitis as the main pathological change. It is critical to explore potential new therapeutic agents to address KD disease and its complications. Ursolic acid (UA) is a pentacyclic triterpene (PT) carboxylic acid that has a number of important pharmacological activities, however, the possible effects of UA on the progression of KD and the mechanism are still unclear. Here we investigated the effects of UA on KD. We revealed that UA improved arterial injury in KD mice. UA improved vascular inflammation in KD mice. In addition, Ursolic suppressed NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome activation. We further found UA restrained vascular smooth muscle cell (VSMC) dedifferentiation, therefore suppressing KD progression. In summary, UA suppressed NLRP3 inflammasome activation as well as alleviated vascular smooth muscle injury in KD. We thought UA could act as a drug of KD.


Keywords

Kawasaki disease (KD); Ursolic acid (UA); Inflammation; NLRP3 inflammasome; Dedifferentiation


Cite and Share

Guoqing Chen,Yanru Wang,Ying Zhang,Fang Gu,Tong Yu. Ursolic acid inhibits NLRP3 inflammasome activation and alleviates vascular smooth muscle injury in Kawasaki disease. Signa Vitae. 2024. 20(4);46-51.

References

[1] Mohankumar SP, Das S, Likitha P, Naranje P, Jana M, Gupta SK, et al. Kawasaki disease or polyarteritis nodosa: coronary involvement, a diagnostic conundrum. Rheumatology International. 2023; 43: 2327–2331.

[2] Duan Y, Li H, Luo D, Jiang J, Liu B, Li G. Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease. International Immunopharmacology. 2023; 122: 110600.

[3] Barman P, Nadig PL, Samynathan P, Jindal AK, Singh S. Malar rash in a febrile infant: is this Kawasaki disease? Rheumatology. 2024; 63: e24–e25.

[4] Li J, Yan W, Ren F, Sang H. Tectorigenin inhibits inflammation in keratinocytes by inhibition of NLRP3 inflammasome regulated by the TLR4/NF-κB pathway. Allergologia et Immunopathologia. 2023; 51: 82–89.

[5] Kobayashi H, Kimura MY, Hasegawa I, Suganuma E, Ikehara Y, Azuma K, et al. Increased Myosin light chain 9 expression during Kawasaki disease vasculitis. Frontiers in Immunology. 2022; 13: 1036672.

[6] Thadchanamoorthy V, Dayasiri K, Ragunathan IR. Atypical Kawasaki disease presenting with macroscopic hematuria in an infant: a case report. Journal of Medical Case Reports. 2023; 17: 10.

[7] Lin J, Harahsheh AS, Raghuveer G, Jain S, Choueiter NF, Garrido-Garcia LM, et al. Emerging insights into the pathophysiology of multisystem inflammatory syndrome associated with COVID-19 in children. Canadian Journal of Cardiology. 2023; 39: 793–802.

[8] Liu L, Huan L, Zhang Y, Wei W, Chen Z, Xu D, et al. Ubiquitin-specific protease 8 inhibits lipopolysaccharide-triggered pyroptosis of human bronchial epithelial cells by regulating PI3K/AKT and NF-κB pathways. Allergologia et Immunopathologia. 2022; 50: 96–103.

[9] Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T. Intravenous immunoglobulin for the treatment of Kawasaki disease. Cochrane Database of Systematic Reviews. 2023; 1: CD014884.

[10] Liu Y, Xia H, Guo S, Li P, Qin S, Shi M, et al. Effect and mechanism of edible oil co-digestion on the bioaccessibility and bioavailability of ursolic acid. Food Chemistry. 2023; 423: 136220.

[11] Kamatchi PAC, Maheswaran R, Sivanandhan S, Ignacimuthu S, Balakrishna K, Reegan AD, et al. Bioefficacy of ursolic acid and its derivatives isolated from Catharanthus roseus (L) G. Don leaf against Aedes aegypti, Culex quinquefasciatus, and Anopheles stephensi larvae. Environmental Science and Pollution Research International. 2023; 30: 69321–69329.

[12] Kornel A, Nadile M, Retsidou MI, Sakellakis M, Gioti K, Beloukas A, et al. Ursolic acid against prostate and urogenital cancers: a review of in vitro and in vivo studies. International Journal of Molecular Sciences. 2023; 24: 7414.

[13] Li Y, Zhao L, Zhao Q, Zhou Y, Zhou L, Song P, et al. Ursolic acid nanoparticles for glioblastoma therapy. Nanomedicine. 2023; 50: 102684.

[14] Zhu L, Tian Y, Wang T, Huang X, Zhou L, Shengming L, et al. Semisynthesis, anti-oomycete and anti-fungal activities of ursolic acid ester derivatives. Natural Product Research. 2024; 38: 906–915.

[15] Luo F, Zhao J, Liu S, Xue Y, Tang D, Yang J, et al. Ursolic acid augments the chemosensitivity of drug-resistant breast cancer cells to doxorubicin by AMPK-mediated mitochondrial dysfunction. Biochemical Pharmacology. 2022; 205: 115278.

[16] Wan S, Luo F, Huang C, Liu C, Luo Q, Zhu X. Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways. Aging. 2020; 12: 10614–10632.

[17] Wang C, Gao Y, Zhang Z, Chen C, Chi Q, Xu K, et al. Ursolic acid protects chondrocytes, exhibits anti-inflammatory properties via regulation of the NF-κB/NLRP3 inflammasome pathway and ameliorates osteoarthritis. Biomedicine & Pharmacotherapy. 2020; 130: 110568.

[18] Yang Y, Luan Y. Editorial: recent advances in mitochondria-associated endoplasmic reticulum membranes (MAMs) in heart-related diseases. Frontiers in Cardiovascular Medicine. 2023; 10: 1168152.

[19] Chu M, Wu R, Qin S, Hua W, Shan Z, Rong X, et al. Bone marrow–derived MicroRNA-223 works as an endocrine genetic signal in vascular endothelial cells and participates in vascular injury from Kawasaki disease. Journal of the American Heart Association. 2017; 6: e004878.

[20] Stojanovic V, Radovanović T, Koprivšek K, Vijatov Ðurić G, Doronjski A. Kawasaki disease complicated with cerebral vasculitis and severe encephalitis. Annals of Indian Academy of Neurology. 2020; 23: 228–232.

[21] Daga MA, Nicolau ST, Jurumenha‐Barreto J, Lima LBS, Cabral IL, Pivotto AP, et al. Ursolic acid-rich extract presents trypanocidal action in vitro but worsens mice under experimental acute Chagas disease. Parasite Immunology. 2023; 45: e13005.

[22] Shi Z, Huang X, Zhao Y, Li J, Tian YQ, Zhang PP, et al. Construction of a novel ursolic acid-based supramolecular gel for efficient removal of iodine from solution. Environmental Research. 2023; 235: 116617.

[23] Yenigün S, Başar Y, İpek Y, Behçet L, Özen T, Demirtaş İ. Determination of antioxidant, DNA protection, enzyme inhibition potential and molecular docking studies of a biomarker ursolic acid in Nepeta species. To be published in Journal of Biomolecular Structure & Dynamics. 2023. [Preprint].

[24] Fan L, Wang X, Cheng C, Wang S, Li X, Cui J, et al. Inhibitory effect and mechanism of ursolic acid on cisplatin-induced resistance and stemness in human lung cancer a549 cells. Evidence-Based Complementary and Alternative Medicine. 2023; 2023: 1–16.

[25] Checker R, Sandur SK, Sharma D, Patwardhan RS, Jayakumar S, Kohli V, et al. Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-κB, AP-1 and NF-AT. PLOS ONE. 2012; 7: e31318.

[26] Li X, Zhang P, Yin Z, Xu F, Yang Z, Jin J, et al. Caspase-1 and Gasdermin D afford the optimal targets with distinct switching strategies in NLRP1b inflammasome-induced cell death. Research. 2022; 2022: 9838341.

[27] Jin Y, Liu Y, Xu L, Xu J, Xiong Y, Peng Y, et al. Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis. Cell Death & Disease. 2022; 13: 512.

[28] Dou X, Qiao L, Chang J, Yan S, Song X, Chen Y, et al. Lactobacillus casei ATCC 393 and it’s metabolites alleviate dextran sulphate sodium-induced ulcerative colitis in mice through the NLRP3-(Caspase-1)/IL-1β pathway. Food & Function. 2021; 12: 12022–12035.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top